Abstract
AbstractLung cancer has a high prevalence and mortality due to its late diagnosis and limited treatment, so it is essential to find biomarkers that allow a faster diagnosis and improve the survival of these patients. In this sense, biomarkers based on miRNAs have supposed a considerable advance. miRNAs, which are small RNA sequences, can regulate gene expression, so they play an essential role not only as a diagnostic biomarker but also as a therapeutic and prognostic one. Also, miRNA biomarkers can be obtained from liquid biopsies, which are less intrusive than lung biopsies, and have better accessibility, safety and repeatability, which allows using those biomarkers both for diagnosis and monitoring of patients. In this review, we highlight the importance of miRNAs and collect the existing evidence of their relationship with lung cancer.
Publisher
Springer Science and Business Media LLC
Subject
Genetics,Molecular Biology,General Medicine
Reference18 articles.
1. Wadowska K, Bil-Lula I, Trembecki ł, Śliwińska-Mossoń M (2020) Genetic markers in lung cancer diagnosis: a review. Int J Mol Sci 21(13):4569
2. Maharjan N, Thapa N, Tu J (2020) Blood-based biomarkers for early diagnosis of lung cancer: a review article. JNMA: J Nepal Med Association 58(227):519
3. Marrugo-Ramírez J, Mir M, Samitier J (2018) Blood-based cancer biomarkers in liquid biopsy: a promising non-invasive alternative to tissue biopsy. Int J Mol Sci 19(10):2877
4. Wang J, Chang S, Li G, Sun Y (2017) Application of liquid biopsy in precision medicine: opportunities and challenges. Front Med 11(4):522–527
5. Pisapia P, Costa JL, Pepe F, Russo G, Gragnano G, Russo A et al (2021) Next generation sequencing for liquid biopsy based testing in Non-Small Cell Lung Cancer in 2021. Crit Rev Oncol/Hematol. ;p. 103311
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献